Compact Ozone Sterilizer Eliminates Contaminants and Germs
The Ozilla from AMSBIO is a new high quality, purpose-built ozone gas generator. Measuring just 13 x 11 x 5 inches (32 x 28 x 13 cm), it will fit in most standard laboratory cell culture incubators, air incubators, cell culture hoods, PCR hoods, or any other environment where a sterile atmosphere is critical. Following simple operational instructions the Ozilla is able to completely eliminate airborne and surface contaminants and germs including bacteria, phage and fungus.
Ozone is the most powerful oxidative agent that occurs naturally. With its extra free radical oxygen molecule, ozone is able to destroy germs, viruses, and microbes that may cause surface or air contamination. Furthermore, ozone leaves no chemical residue typical of alternative detergent or synthetic cleaners, and if handled properly — by converting ozone back to oxygen molecules — it can be one of the most effective sterilizing tools. Ozone is a powerful and natural purifier, and now with the Ozilla Ozone Sterilizer, it is safer and easier than ever to use ozone gas for sterilizing and deodorizing lightly contaminated pipettes, pipette tips, gloves, plates, small instruments, and even personal items such as keys and glasses.
The Ozilla sterilizer is easy and safe to use, and has a novel "scrubbing" technology that removes all ozone gases at the end of each sterilization cycle, by converting ozone gas back to oxygen. As an added advantage, the Ozilla air sterilizer will leave your room or cabinet odor-free and smelling fresh, clean, and ready for your next usage.
With the Ozilla Ozone Sterilizer, there is no longer a need to spend substantial amounts of time and money to plan and deal with the complexity of chemical decontaminations. Other than negating the labor and time waste, the Ozilla device eliminates exposure to toxic chemicals, and removes the possibility of chemical residue accumulation.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.